Kerrisdale Capital, a private investment manager, has published a new report explaining its short position in CareDx, Inc. (NASDAQ: CDNA), a $1.7bn diagnostics company that develops tests for transplant recipients and whose market value is based primarily on AlloSure, a non-invasive test meant to detect kidney rejection
July 16, 2019
· 1 min read